English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, June 2, 2025
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
エーザイ、国内 OTC 医薬品初となるプロトンポンプ阻害薬「パリエット(R) S」新発売
Thursday, May 29, 2025
エーザイ、米国におけるレンバチニブに関する特許侵害訴訟の勝訴について
Wednesday, May 28, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
Wednesday, May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表
Friday, May 16, 2025
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
Wednesday, April 30, 2025
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Friday, April 18, 2025
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Wednesday, April 16, 2025
エーザイとバイオジェン、「レケンビ」(レカネマブ)が欧州連合(EU)において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575